A combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma b-thromboglobulin levels in patients with documented peripheral arterial disease - Hoet, B; Amout, J; Van Geet, C; Deckmyn, H; Verhaeghe, R; Vermylen, J; Ridogre, l (Thromb Haemostas, 1990)